U.S. markets close in 2 hours
  • S&P 500

    3,817.47
    +49.00 (+1.30%)
     
  • Dow 30

    31,338.85
    +414.71 (+1.34%)
     
  • Nasdaq

    12,824.56
    +101.09 (+0.79%)
     
  • Russell 2000

    2,166.46
    +19.53 (+0.91%)
     
  • Crude Oil

    66.15
    +2.32 (+3.63%)
     
  • Gold

    1,697.90
    -2.80 (-0.16%)
     
  • Silver

    25.27
    -0.19 (-0.75%)
     
  • EUR/USD

    1.1918
    -0.0061 (-0.51%)
     
  • 10-Yr Bond

    1.5570
    +0.0070 (+0.45%)
     
  • GBP/USD

    1.3836
    -0.0058 (-0.42%)
     
  • USD/JPY

    108.2860
    +0.3100 (+0.29%)
     
  • BTC-USD

    48,466.19
    -78.24 (-0.16%)
     
  • CMC Crypto 200

    969.69
    +26.52 (+2.81%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.79 (-0.23%)
     

Return On Capital Employed Overview: Vir Biotechnology

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Vir Biotechnology (NASDAQ: VIR) reported Q2 sales of $66.99 million. Earnings fell to a loss of $29.05 million, resulting in a 59.6% decrease from last quarter. Vir Biotechnology collected $5.72 million in revenue during Q1, but reported earnings showed a $71.91 million loss.

What Is ROCE?

Changes in earnings and sales indicate shifts in Vir Biotechnology’s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, Vir Biotechnology posted an ROCE of -0.05%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.

View more earnings on VIR

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

In Vir Biotechnology's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.

Q2 Earnings Insight

Vir Biotechnology reported Q2 earnings per share at $-0.27/share, which beat analyst predictions of $-0.62/share.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.